Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine headaches with or without aura.

Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine headaches with or without aura.
Tukysa (tucatinib) is a medication used in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced, unresectable or metastatic HER2-positive breast cancer.
Radicut (edaravone) and Radicava (edaravone) is a medication for the treatment of patients with amyotrophic lateral sclerosis (ALS) and acute ischaemic stroke.
Trodelvy (sacituzumab govitecan-hziy) is an immune targeted therapy used for the 3rd line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
Tagrisso (osimertinib) is a kinase inhibitor (targeted therapy) medication.
Vyndaqel (tafamidis) is a medicine indicated for the treatment of transthyretin amyloidosis in patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
Tibsovo (ivosidenib) is an IDH1 inhibitor (targeted therapy) medication.
Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate targeted therapy.
Aimovig (erenumab) is a preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks
5 common questions about the supplement that may be useful for ALS, Parkinson's and Alzheimers.